RecruitingPancreatic CancerCancer Cachexia
A First-in-Human Study of FID-022 in Solid Tumor Patients
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This observational study aims to (1) validate a multimodal artificial intelligence (AI) model for early detection of cancer-associated cachexia in pancreatic cancer patients and (2) assess the feasibility and acceptability of diet and exercise interventions for cachexia management. The study will use retrospective data from the Florida Pancreas Collaborative and prospective data from newly diagnosed patients at Moffitt Cancer Center.
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
You may qualify if…
- ✓ Age ≥ 18 years
- ✓ Histologically or cytologically confirmed diagnosis of pancreatic exocrine malignancy (e.g.pancreatic ductal adenocarcinoma, acinar cell carcinoma, pancreatic adenosquamous carcinoma, etc.) or clinical features highly suggestive of such malignancy with diagnostic confirmation anticipated during the screening or early study period.
- ✓ Presentation consistent with resectable, borderline resectable, local, or locally advanced, or metastatic disease
- ✓ May or may not have had surgery
- ✓ Treatment plan likely includes systemic therapy for pancreatic cancer
- ✓ ECOG performance status 0-2
- ✓ Able to tolerate oral intake and not currently receiving enteral or parenteral nutrition
- ✓ Able to read and speak English
You may not qualify if…
- ✕ Pregnant or breastfeeding at the time of enrollment
- ✕ Current use of tube feeding (enteral) or total parenteral nutrition
- ✕ Presence of ascites or other findings suggestive of decompensated disease
- ✕ Evidence or history of bowel obstruction or any gastrointestinal condition that may limit food intake
- ✕ Severe or uncontrolled psychiatric illness (e.g., psychosis, dementia) that would interfere with participation
- ✕ Presence of other uncontrolled intercurrent illnesses (e.g., infection, heart failure, liver failure) that may interfere with protocol adherence
Where it's recruiting
Florida
Tampa
Source: ClinicalTrials.gov · NCT07249775 · last updated 2026-01-28